Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Sunday Times (Johannesburg) - July 25, 2009
Claire Keeton
Dr Pedro Cahn, a past president of the International Aids Society, which is meeting in Cape Town, said: "Everyone agrees that a CD4 of 350 should be the minimum standard."
CD4 tests measure immune strength; in South Africa, the policy is that patients are offered Aids drugs in the public health system when their CD4 count drops to 200 and below, or they develop complications.
In fact, most patients start therapy with far lower CD4 counts, said Dr Francois Venter, president of the HIV Clinicians Society of Southern Africa, as they tend to seek medical help only when they fall sick, and not as the result of regular testing.
If patients with CD4s of 350 were offered treatment, the number of people needing the drugs would soar. In the past seven years, about four million people worldwide (about 600000 of them in South Africa) have been put on antiretrovirals, and about six million more need treatment at the CD4 threshold of 200.
One model showed earlier treatment would save lives and be more cost-effective by preventing opportunistic infections and reducing the burden on health systems.
Dr Wafaa El-Sadr, director of the International Centre for Aids Care and Treatment Programmes in the US, said the world had seen a dramatic decline in Aids deaths since 1996 - but now non-Aids -related mortality was increasing.
She said that people with HIV were at higher risk of dying from non-Aids related diseases as they aged, like stroke or renal failure, than those without the virus. El-Sadr said studies had shown that deferring treatment increased the risk of death.
Another urgent message from the conference was to replace the drug Stavudine (d4T), used in most first-line antiretroviral programmes, including in South Africa. It has side effects such as toxicity and lipoatrophy - the localised loss of fat tissue.
"This conference should be the one to say thank you very much d4T, goodbye and never come back again," said Cahn.
090725
ST090705
Copyright © 2009 - The Sunday Times. Reproduction of this article (other than one copy for personal reference) must be cleared through the Sunday Times Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .